drugset / Trial / NCT00136331

Study of a Pandemic Influenza Vaccine

NCT00136331 ↗

Phase 1 Completed 400 enrolled Seqirus
RandomizedParallel-groupSingle-blindPrevention

Summary

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.

Timeline

Start
2005-10
Primary completion
—
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pandemic Influenza Vaccine Vaccine 7.5 ug —
Subject Pandemic Influenza Vaccine Vaccine 15 ug —

Indications